Showing posts with label Docetaxel. Show all posts
Showing posts with label Docetaxel. Show all posts
Thursday, May 10, 2012
paywalled: Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients:
Background:
To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment.
Conclusion:
Permanent and severe alopecia is a newly reported complication of the FEC 100–docetaxel breast cancer regimen.
add your opinions
adverse effects
,
chemotherapy induced alopecia
,
Cyclophosphamide
,
Docetaxel
,
epirubicin
,
fluorouracil
,
longterm side effects
,
permanent hair loss
Thursday, April 05, 2012
abstract: Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer
Abstract
To evaluate the activity of gemcitabine and docetaxel in patients with recurrent ovarian cancer.
Methods:
Patients with platinum-resistant disease and prior treatment with paclitaxel received treatment with docetaxel on day 1 and gemcitabine on days 1 and 8, repeated every three weeks.
Results:
Twenty patients, with a platinum-free interval of three months, were enrolled. Overall response rate was 25%. Treatment was associated with significant myelosuppression.
Conclusions:
In chemotherapy-resistant patients, this regimen exhibited encouraging activity. Excessive myelosuppression led to early closure. This was prevented by administering docetaxel on day 8 (instead of day 1) and prophylactic use of G-CSF. (blood products)
Methods:
Patients with platinum-resistant disease and prior treatment with paclitaxel received treatment with docetaxel on day 1 and gemcitabine on days 1 and 8, repeated every three weeks.
Results:
Twenty patients, with a platinum-free interval of three months, were enrolled. Overall response rate was 25%. Treatment was associated with significant myelosuppression.
Conclusions:
In chemotherapy-resistant patients, this regimen exhibited encouraging activity. Excessive myelosuppression led to early closure. This was prevented by administering docetaxel on day 8 (instead of day 1) and prophylactic use of G-CSF. (blood products)
add your opinions
Docetaxel
,
G-CSF
,
Gemcitabine
,
myelosuppression
,
platinum resistant
,
treatment related side effects
Tuesday, January 03, 2012
Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
Objectives:
The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of patients with advanced-stage ovarian carcinoma treated with a first-line weekly docetaxel and 3 weekly carboplatin regimen.
Conclusions:
The tolerable hematologic toxicity (no need for colony-stimulating factors) and the low rate of neurotoxicity (only grades 1–2) and response rates in line with the standard 3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma after suboptimal cytoreductive surgery make this regimen an interesting alternative in selected patients.
add your opinions
Carboplatin
,
Docetaxel
,
Paclitaxel
,
Taxol
,
weekly
Sunday, June 12, 2011
abstract: Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication
Purpose: Anaphylactic reactions (ARs) have been frequently reported with taxanes. The authors' purpose was to summarize published case reports and describe ARs from taxanes reported to the Food and Drug Administration (FDA) with a focus on use of package insert-specified prophylactic premedications (PPMs).
Conclusions: Mortality was reported in more docetaxel ARs than paclitaxel. Documented use of PPMs did not significantly impact mortality from ARs with docetaxel, but was associated with significantly lower mortality from ARs with paclitaxel.
add your opinions
adverse events
,
Anaphylactic reactions
,
cancer mortality
,
Docetaxel
,
longterm side effects
,
Paclitaxel
,
Taxol
Saturday, May 28, 2011
abstract: Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer
CONCLUSIONS:
Combined weekly cDC (concurrent docetaxel and carboplatin) appeared to
be cost-effective compared with sDC (sequential docetaxel and carboplatin ) as treatment strategy for patients
with platinum-sensitive ovarian cancer, even when accounting for
slightly lower QoL during treatment.
add your opinions
cancer costs
,
Carboplatin
,
concurrent
,
Docetaxel
,
economics
,
QOL
,
sequential
,
treatments
Monday, February 21, 2011
Letter to the Editor: Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer
Note: no abstract/pay-per-view (subscription req'd $$$)
add your opinions
Carboplatin
,
Docetaxel
,
erlotinib
,
toxicity
Sunday, December 19, 2010
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group
CONCLUSIONS: This combination was well tolerated and appears more active than the historical control of single agent taxane therapy in those with recurrent ovarian and peritoneal cancer after failing multiple lines of chemotherapy. Further study is warranted
add your opinions
Docetaxel
,
trabectedin
Tuesday, August 24, 2010
Thursday, June 10, 2010
Thursday, March 18, 2010
Medical News: SGO: Drug Combination Slows Recurrent Ovarian Cancer - Taxotere + Carboplatin
"Median PFS was almost 14 months with combination therapy, while sequential administration of docetaxel (Taxotere) and carboplatin was associated with a median PFS of about eight months."
add your opinions
Carboplatin
,
Docetaxel
,
Taxotere
Subscribe to:
Posts
(
Atom
)